Fenwick represented Day One Biopharmaceuticals, Inc. on the offering, while Cooley LLP represented the underwriters. Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company focused...
Day One Biopharmaceuticals’ $150 Million Public Offering
Day One Biopharmaceuticals’ IPO
Wilson Sonsini Goodrich & Rosati and Fenwick & West LLP advised Day One Biopharmaceuticals on the deal. San Francisco-based Day One Biopharmaceuticals, a Phase 2 biotech...
Day One Biopharmaceuticals’ Licensing Agreement with Merck KGaA
Fenwick & West LLP advised Day One Biopharmaceuticals on the deal. Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating new targeted therapies for children...
Day One Biopharmaceuticals’ $130 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised Day One Biopharmaceuticals on the deal. Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating new, promising targeted therapies...